Revenue: As of FY2025 Q3, the actual value is USD 49.3 M.EPS: As of FY2025 Q3, the actual value is USD 0.7.EBIT: As of FY2025 Q3, the actual value is USD -6.749 M.<h3>Revenue</h3><ul><li>Three Months Ended September 30, 2025: $49,298 thousand</li><li>Three Months Ended September 30, 2024: $36,062 thousand</li><li>Nine Months Ended September 30, 2025: $130,354 thousand</li><li>Nine Months Ended September 30, 2024: $110,429 thousand</li></ul><h3>Cost of Revenue</h3><ul><li>Three Months Ended September 30, 2025: $37,684 thousand</li><li>Three Months Ended September 30, 2024: $28,554 thousand</li><li>Nine Months Ended September 30, 2025: $100,898 thousand</li><li>Nine Months Ended September 30, 2024: $85,854 thousand</li></ul><h3>Software Development</h3><ul><li>Three Months Ended September 30, 2025: $453 thousand</li><li>Three Months Ended September 30, 2024: $417 thousand</li><li>Nine Months Ended September 30, 2025: $1,354 thousand</li><li>Nine Months Ended September 30, 2024: $1,031 thousand</li></ul><h3>General and Administrative</h3><ul><li>Three Months Ended September 30, 2025: $16,301 thousand</li><li>Three Months Ended September 30, 2024: $13,869 thousand</li><li>Nine Months Ended September 30, 2025: $42,954 thousand</li><li>Nine Months Ended September 30, 2024: $39,140 thousand</li></ul><h3>Selling and Marketing</h3><ul><li>Three Months Ended September 30, 2025: $482 thousand</li><li>Three Months Ended September 30, 2024: $314 thousand</li><li>Nine Months Ended September 30, 2025: $1,096 thousand</li><li>Nine Months Ended September 30, 2024: $1,025 thousand</li></ul><h3>Operating Loss from Continuing Operations</h3><ul><li>Three Months Ended September 30, 2025: -$5,622 thousand</li><li>Three Months Ended September 30, 2024: -$7,092 thousand</li><li>Nine Months Ended September 30, 2025: -$15,948 thousand</li><li>Nine Months Ended September 30, 2024: -$16,621 thousand</li></ul><h3>Other Non-Operating Income (Loss)</h3><ul><li>Interest Income<ul><li>Three Months Ended September 30, 2025: $1,127 thousand</li><li>Three Months Ended September 30, 2024: $1,764 thousand</li><li>Nine Months Ended September 30, 2025: $3,603 thousand</li><li>Nine Months Ended September 30, 2024: $5,624 thousand</li></ul></li><li>Change in Fair Value of Warrant Liabilities<ul><li>Three Months Ended September 30, 2025: $33 thousand</li><li>Three Months Ended September 30, 2024: -$299 thousand</li><li>Nine Months Ended September 30, 2025: $2,862 thousand</li><li>Nine Months Ended September 30, 2024: $2,266 thousand</li></ul></li><li>Realized Loss from Sales of Short-Term Investments<ul><li>Three Months Ended September 30, 2025: -$5,195 thousand</li><li>Nine Months Ended September 30, 2025: -$5,195 thousand</li></ul></li></ul><h3>Loss from Continuing Operations Before Income Taxes</h3><ul><li>Three Months Ended September 30, 2025: -$9,657 thousand</li><li>Three Months Ended September 30, 2024: -$5,627 thousand</li><li>Nine Months Ended September 30, 2025: -$14,678 thousand</li><li>Nine Months Ended September 30, 2024: -$8,731 thousand</li></ul><h3>Net Loss from Continuing Operations</h3><ul><li>Three Months Ended September 30, 2025: -$9,657 thousand</li><li>Three Months Ended September 30, 2024: -$5,627 thousand</li><li>Nine Months Ended September 30, 2025: -$14,678 thousand</li><li>Nine Months Ended September 30, 2024: -$8,731 thousand</li></ul><h3>Net Income (Loss) from Discontinued Operations</h3><ul><li>Three Months Ended September 30, 2025: $67,073 thousand</li><li>Three Months Ended September 30, 2024: $3,673 thousand</li><li>Nine Months Ended September 30, 2025: $64,858 thousand</li><li>Nine Months Ended September 30, 2024: -$8,783 thousand</li></ul><h3>Net Income (Loss)</h3><ul><li>Three Months Ended September 30, 2025: $57,416 thousand</li><li>Three Months Ended September 30, 2024: -$1,954 thousand</li><li>Nine Months Ended September 30, 2025: $50,180 thousand</li><li>Nine Months Ended September 30, 2024: -$17,514 thousand</li></ul><h3>Basic and Diluted Earnings (Loss) Per Share</h3><ul><li>Continuing Operations<ul><li>Three Months Ended September 30, 2025: -$0.12</li><li>Three Months Ended September 30, 2024: -$0.07</li><li>Nine Months Ended September 30, 2025: -$0.18</li><li>Nine Months Ended September 30, 2024: -$0.11</li></ul></li><li>Discontinued Operations<ul><li>Three Months Ended September 30, 2025: $0.81</li><li>Three Months Ended September 30, 2024: $0.05</li><li>Nine Months Ended September 30, 2025: $0.80</li><li>Nine Months Ended September 30, 2024: -$0.11</li></ul></li><li>Total Basic and Diluted Earnings (Loss) Per Share<ul><li>Three Months Ended September 30, 2025: $0.70</li><li>Three Months Ended September 30, 2024: -$0.03</li><li>Nine Months Ended September 30, 2025: $0.62</li><li>Nine Months Ended September 30, 2024: -$0.23</li></ul></li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities<ul><li>Nine Months Ended September 30, 2025: -$40,607 thousand</li><li>Nine Months Ended September 30, 2024: -$767 thousand</li></ul></li><li>Net Cash Provided by / (Used in) Investing Activities<ul><li>Nine Months Ended September 30, 2025: $51,485 thousand</li><li>Nine Months Ended September 30, 2024: -$4,992 thousand</li></ul></li><li>Net Cash Used in Financing Activities<ul><li>Nine Months Ended September 30, 2025: -$7,170 thousand</li><li>Nine Months Ended September 30, 2024: -$1,885 thousand</li></ul></li><li>Effect of Foreign Exchange Rate Changes on Cash Balances<ul><li>Nine Months Ended September 30, 2025: -$339 thousand</li><li>Nine Months Ended September 30, 2024: $29 thousand</li></ul></li><li>Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash<ul><li>Nine Months Ended September 30, 2025: $3,369 thousand</li><li>Nine Months Ended September 30, 2024: -$7,615 thousand</li></ul></li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company aims to leverage its expertise and resources to provide other medical and logistics services to a broader customer base, closely aligning its goals with those of all participants in the transplant ecosystem, including transplant centers, regulators, Organ Procurement Organizations (OPOs), and other service providers.</li><li>Non-Core Business: The company completed the sale of its Passenger business to Joby Aero, Inc. on August 29, 2025, and the acquisition of Keystone Perfusion Services, LLC on September 16, 2025. The company expects to realize various benefits from these transactions, including cost efficiencies and accretive benefits, and aims to successfully integrate Keystone and retain its key employees and clients.</li><li>Priority: The company anticipates that it has sufficient funds to meet its current operational needs for at least the next 12 months from the date of filing this Quarterly Report. The company may seek external sources of financing in the future to take advantage of market opportunities.</li></ul>

STRATA CRITICAL MED INC C/WTS 07/05/2026 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 49.3 M